Expert Interview
Taking a look at the ongoing NTLA's study of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy and BBIO's phase 3 attribute-cm study of acoramidis in patients with transthyretin (ATTR) amyloidosis
Ticker(s): NTLA, BBIOInstitution: UCL
- Founder of UK National Amyloidosis Centre, opened 1999.
- 35 years specialising in amyloidosis as a clinician and researcher.
- Expert knowledge on pathogenesis, diagnosis, investigation and treatment of all forms of systemic amyloidosis. Published more than 400 papers on the subject.
- Have been PI in the past on many basic, translational and clinical studies
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
